Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without tremelimumab versus standard chemotherapy as first-line treatment for advanced urothelial carcinoma
CTR20190596Phase 3Completed
- Sponsor
- MedImmune
- Start
- May 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in transitional cell carcinoma (TCC), sponsored by MedImmune. Started May 2020; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20190596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190596.